Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

Exclusion Criteria

• •Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening
• •History or presence of chronic or recurrent pancreatitis
• •History of malignant neoplasms within the past 5 years prior to screening
• •Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2
• •Is currently using other medications for weight loss or other GLP-1 receptor agonists
• •Has a history of allergy or sensitivity to Semaglutide
• •Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
• •Has untreated hypertension with a seated systolic blood pressure \> 160 mmHg, diastolic blood pressure \> 100 mmHg, or heart rate \> 100 beats/minute
• •Has current uncontrolled hypertension
• •Has current uncontrolled Type I or Type II diabetes mellitus
• •Has untreated hypothyroidism with a TSH \> 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit
• •Has active gallbladder disease
• •Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder
• •Has a recent history of substance use disorder (with the exception of cannabis or tobacco use disorder) within the past 12 months
• •Is currently engaging in other treatment for Alcohol Use Disorder or making intentional efforts to quit alcohol use
• •Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device
• •Is breast-feeding, pregnant, or not using a reliable form of birth control
• •Reports active suicidal or homicidal ideation